Forte Biosciences (FBRX) Cash from Financing Activities (2016 - 2026)
Forte Biosciences' (FBRX) quarterly Cash from Financing Activities came in at $74000.0 in Q1 2026, up 103.19% year-on-year from $36419.7 in Q1 2025, and up 722.22% on a QoQ basis from $9000.0 in Q4 2025.
Forte Biosciences (FBRX) Cash from Financing Activities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Cash from Financing Activities data on file, last reported at $74000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 103.19% year-over-year to $74000.0 in Q1 2026; TTM through Mar 2026 was $71.8 million, a 44.84% increase from a year earlier, with the FY2025 full-year figure at $69.4 million, up 33.75% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $74000.0, up from $9000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for FBRX reached as high as $70.3 million in Q2 2025 and fell as low as -$2.3 million in Q1 2025.
- Historically, Cash from Financing Activities has averaged $9.0 million across 5 years, with a median of -$2000.0 in 2024.
- On a YoY basis, Cash from Financing Activities climbed as much as 703590.0% in 2025 and fell as far as 28925.0% in 2025.
- Year by year, Cash from Financing Activities stood at -$55000.0 in 2022, then sank by 36.36% to -$75000.0 in 2023, then jumped by 69269.33% to $51.9 million in 2024, then sank by 99.98% to $9000.0 in 2025, then jumped by 722.22% to $74000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $74000.0 in Q1 2026, $9000.0 in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - | 74,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 1.33 Mn |
| Sep 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 70.35 Mn |
| Jun 30, 2025 | 70.35 Mn |
| Mar 31, 2025 | -2.32 Mn |
| Mar 31, 2025 | -2.32 Mn |
| Dec 31, 2024 | 51.88 Mn |
| Dec 31, 2024 | 51.88 Mn |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | -75,000.00 |
| Dec 31, 2023 | -75,000.00 |